Investors Hangout Stock Message Boards Logo
  • Home
  • Mailbox
  • Boards
  • Favorites
  • Whats Hot!
  • Login - Join Now!
Profile
Rex Eupseiphos's Profile
Displaying 1-50 of 156 result(s).
CYDY CytoDyn Inc
09/04/2020 8:57:49 AM
yes, but politics speak very loudly
CYDY CytoDyn Inc
08/15/2020 11:52:02 AM
severe trial update...not likely be (4)
CYDY CytoDyn Inc
08/07/2020 12:54:59 AM
good result but not statistically s
CYDY CytoDyn Inc
08/01/2020 9:03:35 PM
Enrollment is getting close to 200,
CYDY CytoDyn Inc
07/29/2020 11:49:44 AM
"markets don't seem to care about l (2)
CYDY CytoDyn Inc
07/23/2020 12:37:33 AM
Uh, OK. Let L0, L1, P0, P1 be the n
CYDY CytoDyn Inc
07/22/2020 11:45:26 PM
because the s/c trial is 2:1, there (3)
CYDY CytoDyn Inc
07/22/2020 6:34:17 PM
sorry, CDiddy. I meant to be replyi (1)
CYDY CytoDyn Inc
07/22/2020 6:17:32 PM
m/m trial metrics (5)
CYDY CytoDyn Inc
07/22/2020 10:17:24 AM
Agreed. the SAE/AE data give strong (1)
CYDY CytoDyn Inc
07/21/2020 11:59:44 AM
Nonsensical update to PR: "39% (11 (4)
CYDY CytoDyn Inc
07/21/2020 9:24:30 AM
Because the subhead is apparently w
CYDY CytoDyn Inc
07/21/2020 9:21:07 AM
Let the seller beware! The SP will (5)
CYDY CytoDyn Inc
07/21/2020 8:28:22 AM
Take the S out of the SAE in the su (2)
CYDY CytoDyn Inc
07/21/2020 8:14:20 AM
or "Leronlimab reduces patients wit
CYDY CytoDyn Inc
07/20/2020 10:30:40 PM
disagree. he was talking about medi (7)
CYDY CytoDyn Inc
07/17/2020 5:29:07 PM
No one knows, but exciting biotech
CYDY CytoDyn Inc
07/17/2020 4:43:49 PM
What P/E ratio do you assmue?
CYDY CytoDyn Inc
07/17/2020 4:04:57 PM
He's welcome to play at my table in (1)
CYDY CytoDyn Inc
07/17/2020 3:31:51 PM
and an excited NP on Dr Been tomorr (1)
CYDY CytoDyn Inc
07/17/2020 11:15:58 AM
yep...safe for a nicely coordinated (1)
CYDY CytoDyn Inc
07/15/2020 9:05:35 PM
I'm betting the m/m results are goi (2)
CYDY CytoDyn Inc
07/15/2020 1:19:27 PM
a joke...think about it (1)
CYDY CytoDyn Inc
07/15/2020 12:29:29 PM
Occam's razor...what's that? "It's (1)
CYDY CytoDyn Inc
07/14/2020 10:57:11 AM
thanks, kabonk. I'd forgotten about (3)
CYDY CytoDyn Inc
07/13/2020 8:38:01 PM
excellent explanation, havasu78. th
CYDY CytoDyn Inc
07/13/2020 10:20:41 AM
it's important to get the statistic
CYDY CytoDyn Inc
07/12/2020 12:21:17 PM
Have you seen any measures of viral (1)
CYDY CytoDyn Inc
07/12/2020 12:07:27 PM
Is there a distinction between plas
CYDY CytoDyn Inc
07/12/2020 11:23:51 AM
Thanks, CTMedic! I appreciate the e (3)
CYDY CytoDyn Inc
07/12/2020 11:07:31 AM
Plasma viral load has been detected (2)
CYDY CytoDyn Inc
07/12/2020 10:47:50 AM
Good morning, TechGuru. I hate to g (18)
CYDY CytoDyn Inc
07/11/2020 11:48:36 PM
p-values were large because the sta
CYDY CytoDyn Inc
07/11/2020 9:27:58 PM
this is more credible than the Pers
CYDY CytoDyn Inc
07/11/2020 9:05:23 PM
and he withdrew the post
CYDY CytoDyn Inc
07/10/2020 1:31:05 PM
4, 1, 2, 3...papers are not likely
CYDY CytoDyn Inc
07/10/2020 12:13:15 PM
"submitted" and "going to be publis (1)
CYDY CytoDyn Inc
07/10/2020 12:11:06 PM
There is no "peer review" at medrXi
CYDY CytoDyn Inc
07/09/2020 3:33:31 PM
NP gave a nice presentation of HIV (7)
CYDY CytoDyn Inc
07/09/2020 3:10:30 PM
Dr. Patterson is a scientist, not a (1)
CYDY CytoDyn Inc
07/09/2020 2:17:18 PM
Wow. I hope this is the last time t (6)
CYDY CytoDyn Inc
07/05/2020 9:11:20 PM
yep. The blood work for the trials
CYDY CytoDyn Inc
07/05/2020 7:15:17 PM
havasu78: I am assuming that Patter
CYDY CytoDyn Inc
07/04/2020 1:54:18 PM
profit-taking? Fne. Market manipula
CYDY CytoDyn Inc
07/04/2020 1:55:08 AM
the statistical calculations should
CYDY CytoDyn Inc
07/03/2020 5:14:30 PM
Does HIPAA allow a researcher to do
CYDY CytoDyn Inc
07/03/2020 2:47:51 PM
a few questions, blafarm... The blo (4)
CYDY CytoDyn Inc
07/01/2020 6:29:12 PM
this morning NP said s/c was at 120
CYDY CytoDyn Inc
07/01/2020 6:03:01 PM
the s/c trials involve very little
CYDY CytoDyn Inc
06/26/2020 11:24:48 PM
In the 6/11 CC, MM said they were a (2)
Go to page:
  • << First
  • < Previous
  • 1
  • 2
  • Next >

Recent Articles

  • Johnson & Johnson's IMAAVY Hits Myasthenia Gravis Market
  • Cohen & Steers Total Return Realty Fund Updates for Investors
  • SFC Enhances Community Engagement with New Ice Rink Management
  • Boehringer Ingelheim Unveils Promising Cancer Trials at ASCO 2025
  • Soleno Therapeutics Advances in Treating Hyperphagia for PWS
  • Embracing Peace Through Collective Prayer and Support
  • Understanding Distribution Sources for Cohen & Steers' Fund
  • Innovative Cancer Research from RWJBarnabas Health Surfaces
  • Abeona's ZEVASKYN Breakthrough: A New Hope for DEB Patients
  • Silvercorp Exhibits Strong Fiscal Year-End Performance 2025
  • Univest Securities Completes $5 Million Offering for WORK Medical Tech
  • Kura Oncology and Kyowa Kirin Unveil Ziftomenib Trial Findings
  • Merus Showcases Promising Efficacy of Petosemtamab with Pembrolizumab
  • Iovance Biotherapeutics Reveals 5-Year Study on Amtagvi® Efficacy
  • Daktronics Engages at Leading Investor Conference This May
  • Allogene Therapeutics Shares Key ASCO 2025 Abstracts on CAR T Developments
  • IMUNON Seeks to Withdraw Registration Amid Growth Plans
  • Abcourt Mines Inc. Reports Solid Third Quarter Progress
  • PDS Biotech Shares Positive Results for Versamune® HPV Treatments
  • Servotronics' Proxy Contest Conclusion and Upcoming Meeting
  • Haivision to Unveil Financial Insights for Q2 Fiscal 2025
  • M-tron Industries, Inc. Announces Upcoming Investor Meeting
  • Rigel Pharmaceuticals Set for Major Presentations at ASCO 2025
  • Investors Can Join Digimarc Corporation Class Action Today
  • ImCheck Therapeutics Showcases Promising AML Therapy Results
  • Legend Biotech Reveals Significant Updates in Cancer Treatment
  • ROHM Introduces Next-Gen Compact NIR LEDs for Advanced Applications
  • Cullinan Therapeutics and Partners Showcase Breakthrough Cancer Trial Findings
  • Biodesix Unveils Promising Data on VeriStrat Test for NSCLC
  • Acceleware Ltd. Achieves Significant Progress in Q1 2025
  • Genmab Unveils Late-Stage Data Ahead of ASCO 2025 Meeting
  • Petrus Resources Shares Success of Annual Meeting Outcomes
  • Exciting Phase 2 Results from Actuate's Elraglusib in Cancer Treatment
  • Candel Therapeutics Advances Localized Prostate Cancer Treatment
  • Adagene Showcases Promising Results for ADG126 in Cancer Trials
  • Banco Comercial Português Highlights Key AGM Resolutions
  • Wheaton Precious Metals Unveils 2024 Reports on Sustainability and Climate
  • Novita Reports Encouraging Phase 2 Trial Results for NP-G2-044
  • Accent Therapeutics Showcases Innovative Cancer Treatment Advances
  • Cizzle Bio's CIZ1B Test Offers Significant Medicare Savings
  • Ontario International Airport Sees Record Passenger Growth
  • Foresight Diagnostics Validates CLARITY MRD Assay for DLBCL
  • XTANDI™ Breakthrough: Prostate Cancer Patients See 30% Survival Increase
  • Servier Showcases Commitment to IDH-Mutated Cancer Research
  • West Fraser Timber's Commitment to Sustainability in 2024
  • Boehringer Ingelheim's Ambitious Plan for Future Cancer Innovations
  • Taiho Oncology Unveils Groundbreaking Cancer Therapy Data
  • Eli Lilly Unveils Research Presentations for ASCO 2025 Meeting
  • COOFANDY Celebrates a Decade of Excellence with Major Awards
  • Unlocking Earning Potential: FioBit's AI Mining Revolution 2025
  • Home - Investors HangoutHome

  • Mailbox - Investors HangoutMailbox

  • Boards - Investors HangoutBoards

  • Favorites - Investors HangoutFavorites

  • Whats Hot! - Investors HangoutWhats Hot!

  • More - Investors HangoutMore

  • Settings - Investors HangoutSettings
  • Login - Investors HangoutLogin
  • Live Site - Investors HangoutLive Site